Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,496,359
  • Shares Outstanding, K 107,974
  • Annual Sales, $ 258,000 K
  • Annual Income, $ -283,000 K
  • EBIT $ -375 M
  • EBITDA $ -390 M
  • 60-Month Beta 0.75
  • Price/Sales 9.50
  • Price/Cash Flow N/A
  • Price/Book 5.62

Options Overview Details

View History
  • Implied Volatility 61.46% (-5.35%)
  • Historical Volatility 59.66%
  • IV Percentile 2%
  • IV Rank 4.62%
  • IV High 220.54% on 08/08/25
  • IV Low 53.75% on 01/21/25
  • Expected Move (DTE 22) 2.94 (12.72%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 51
  • Volume Avg (30-Day) 835
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 21,690
  • Open Int (30-Day) 37,967
  • Expected Range 20.18 to 26.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.99
  • Number of Estimates 5
  • High Estimate -0.39
  • Low Estimate -1.17
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +3.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.35 +13.61%
on 12/12/25
26.40 -12.42%
on 12/09/25
-0.06 (-0.26%)
since 11/24/25
3-Month
12.15 +90.29%
on 09/26/25
26.40 -12.42%
on 12/09/25
+10.61 (+84.81%)
since 09/24/25
52-Week
6.50 +255.69%
on 04/07/25
26.40 -12.42%
on 12/09/25
+7.21 (+45.32%)
since 12/24/24

Most Recent Stories

More News
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune...

RCUS : 23.12 (+1.81%)
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell?

Not a collapse, just a pivot toward what matters most. Arcus Biosciences still has plenty of potential.

RCUS : 23.12 (+1.81%)
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development...

RCUS : 23.12 (+1.81%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, inflammatory and...

RCUS : 23.12 (+1.81%)
Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune...

RCUS : 23.12 (+1.81%)
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory...

RCUS : 23.12 (+1.81%)
Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory...

RCUS : 23.12 (+1.81%)
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line...

RCUS : 23.12 (+1.81%)
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International...

RCUS : 23.12 (+1.81%)
Arcus Biosciences Reports Promising Phase 2 Study Results

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

RCUS : 23.12 (+1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

3rd Resistance Point 23.97
2nd Resistance Point 23.57
1st Resistance Point 23.34
Last Price 23.12
1st Support Level 22.71
2nd Support Level 22.31
3rd Support Level 22.08

See More

52-Week High 26.40
Last Price 23.12
Fibonacci 61.8% 18.80
Fibonacci 50% 16.45
Fibonacci 38.2% 14.10
52-Week Low 6.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar